Xanthones from
Rheumatoid arthritis
drug-drug interaction
methotrexate
pharmacokinetics
reduced folate carrier 1
Journal
Immunopharmacology and immunotoxicology
ISSN: 1532-2513
Titre abrégé: Immunopharmacol Immunotoxicol
Pays: England
ID NLM: 8800150
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
pubmed:
20
7
2022
medline:
24
1
2023
entrez:
19
7
2022
Statut:
ppublish
Résumé
The first-line anti-rheumatic drug methotrexate (MTX) is used in the combination. Because of the unpredictable adverse reactions, optimization of relevant regimens is necessary and meaningful. This study aimed to study the possible interaction between We established adjuvant-induced arthritis (AIA) model, which was treated with MTX and MTX + xanthone-rich fraction (XRF). The clinical efficacy was evaluated by histopathological examination, and LC-MS was used to monitor the blood concentration of MTX. Western blotting and immunohistochemistry were used to detect protein expression. Compared with MTX-treated rats, inflammation in the immunized rats in the MTX + XRF group was obvious, indicating that XRF antagonized the anti-rheumatic effect of MTX. Meanwhile, XRF reduced liver and kidney injuries caused by MTX in addition to MTX. Results from immunohistochemical and nappendiculat assays suggested that XRF may reduce uptake of MTX by down-regulating reduced folate carrier 1 (RFC1). This study indicated that XRF could reduce the plasma concentration of MTX by inhibiting the expression of RFC1, antagonize the therapeutic effect of MTX on AIA rats, and reduce its oral bioavailability. The combination of
Sections du résumé
BACKGROUND
UNASSIGNED
The first-line anti-rheumatic drug methotrexate (MTX) is used in the combination. Because of the unpredictable adverse reactions, optimization of relevant regimens is necessary and meaningful. This study aimed to study the possible interaction between
METHODS
UNASSIGNED
We established adjuvant-induced arthritis (AIA) model, which was treated with MTX and MTX + xanthone-rich fraction (XRF). The clinical efficacy was evaluated by histopathological examination, and LC-MS was used to monitor the blood concentration of MTX. Western blotting and immunohistochemistry were used to detect protein expression.
RESULTS
UNASSIGNED
Compared with MTX-treated rats, inflammation in the immunized rats in the MTX + XRF group was obvious, indicating that XRF antagonized the anti-rheumatic effect of MTX. Meanwhile, XRF reduced liver and kidney injuries caused by MTX in addition to MTX. Results from immunohistochemical and nappendiculat assays suggested that XRF may reduce uptake of MTX by down-regulating reduced folate carrier 1 (RFC1).
CONCLUSION
UNASSIGNED
This study indicated that XRF could reduce the plasma concentration of MTX by inhibiting the expression of RFC1, antagonize the therapeutic effect of MTX on AIA rats, and reduce its oral bioavailability. The combination of
Identifiants
pubmed: 35850595
doi: 10.1080/08923973.2022.2103707
doi:
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Reduced Folate Carrier Protein
0
Antirheumatic Agents
0
Xanthones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM